Diagnostic signature for heart failure with preserved ejection fraction (HFpEF): a machine learning approach using multi-modality electronic health record data

• Published in: BMC cardiovascular disorders Vol. 22; no. 1; pp. 567 - 13
• Main Authors: Farajidavar, Nazli, O'Gallagher, Kevin, Bean, Daniel, Nabeebaccus, Adam, Zakeri, Rosita, Bromage, Daniel, Kraljevic, Zeljko, Teo, James T H, Dobson, Richard J, Shah, Ajay M
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 26-12-2022; BioMed Central; BMC
• Subjects: Analysis; Cardiac output; Care and treatment; Diagnosis; Dyspnea; Dyspnea - diagnosis; Electronic Health Records; Electronic records; Evidence-based medicine; Health aspects; Heart failure; Heart Failure - diagnosis; Heart Failure - therapy; HFpEF; Humans; Machine learning; Measurement; Medical records; Methods; Prognosis; Quality of Life; Retrospective Studies; Stroke Volume; Ventricular Function, Left; United Kingdom; Dyspnea; Machine learning; HFpEF
• ISSN: 1471-2261; 1471-2261
• DOI: 10.1186/s12872-022-03005-w

Heart failure with preserved ejection fraction (HFpEF) is thought to be highly prevalent yet remains underdiagnosed. Evidence-based treatments are available that increase quality of life and decrease hospitalization. We sought to develop a data-driven diagnostic model to predict from electronic health records (EHR) the likelihood of HFpEF among patients with unexplained dyspnea and preserved left ventricular EF.
The derivation cohort comprised patients with dyspnea and echocardiography results. Structured and unstructured data were extracted using an automated informatics pipeline. Patients were retrospectively diagnosed as HFpEF (cases), non-HF (control cohort I), or HF with reduced EF (HFrEF; control cohort II). The ability of clinical parameters and investigations to discriminate cases from controls was evaluated by extreme gradient boosting. A likelihood scoring system was developed and validated in a separate test cohort. The derivation cohort included 1585 consecutive patients: 133 cases of HFpEF (9%), 194 non-HF cases (Control cohort I) and 1258 HFrEF cases (Control cohort II). Two HFpEF diagnostic signatures were derived, comprising symptoms, diagnoses and investigation results. A final prediction model was generated based on the averaged likelihood scores from these two models. In a validation cohort consisting of 269 consecutive patients [with 66 HFpEF cases (24.5%)], the diagnostic power of detecting HFpEF had an AUROC of 90% (P < 0.001) and average precision of 74%.
This diagnostic signature enables discrimination of HFpEF from non-cardiac dyspnea or HFrEF from EHR and can assist in the diagnostic evaluation in patients with unexplained dyspnea. This approach will enable identification of HFpEF patients who may then benefit from new evidence-based therapies.